Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Next Previous
Trial Profile

ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SER 287 (Primary) ; Vancomycin
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ECO-RESET
  • Sponsors Seres Therapeutics

    • Most Recent Events

    • 16 Dec 2021 Results presented in a Seres Therapeutics Media Release.
    • 26 Oct 2021 Status changed from active, no longer recruiting to discontinued due to the lack of a clinical efficacy signal in the induction treatment phase. Seres closed the dosing phases of open label and maintenance portions of the study. Patients who had received prior doses were followed for safety data.
    • 03 Aug 2021 According to a Seres Therapeutics media release, the company expects to obtain microbiome data in H2 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top